Blistering Dermatoses Flashcards
1st site of PV
Mouth (60%)> site of injury
MC ab in PV
Dgl 3
Mucocutaneous PV
Dgl 3 + 1
Predominate dgl 3 ab
Mucosal lesions predominate
PV pathophys
Plasminogen activator associated with ab mediated acantholysis
Th 2 ( but Th1 may be involved more in chronic
PV associations
Myesthenia gravis and thymoma
PV treatment
Steroids ā> cellcept > azathioprine
Some consider rituximab first line
Continue meds until ab disappear then repeat DIF to predict remission
Dominant autoimmune epitope in PV and PF
N-terminal extracellular domain of dsg 1
Fogo selvagem
IL-1beta increased, strong Th1, IgM anti dsg 1
% of pts with pemphigus erythematosus and pos lupus band
80%
Dsg 1, BP230, periplakin
Definitive test in PNP
Immunoprecipitation reveals immune response against Desmoplakin, envoplakin, BPAG1, periplakin
Also dsg 1 and 3 - dsg 3 ab epitope spread broadly through the extracellular domain (vs PV)
IgG1 and 2 predominant (vs 4 in PV)
HLA for PNP - significant
HLA-DRB1*03
Ag in localized vulvar BP in young girls
230 kd ag
% of BP with oral
20%
LP pemphigoides ag
230, 180 and unique 200 kd
Anti p-105 pemphigoid
Nonscarring, acute, widespread, severe MM involvement
DIF same as BP
Ag= 105 kd ag in lamina lucida
% with positive circulating anti BM ab in BP
70% Fix C (vs PV) which causes the damage
Site of Ab binding
Lamina Lucida
IgG4
50% with eosinophilia
% in BP with a positive DIF
100%, MC Cā
BP prognosis
Normally self limited over 5 years, less in kids
Associated with increased risk of death in first yr of BP
Circulating 180 (but not 230)
Other RF- old age, high steroid dose at d/c, low albumin, and ESR >30
Generalized inflammatory EBA
Associated diabetes and HLA-DR2
Childhood DH
May also see palmar blisters and brown hemorrhagic purpuric macules
Drug induced grovers
Cetuximab